Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00671424 | A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide | PHASE1 | COMPLETED | 48 | — | — | Mar 1, 2008 | May 1, 2008 | Mar 19, 2012 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Hydrochlorothiazide (HCTZ) | DRUG | - |
| Remogliflozin etabonate (GSK189075) | DRUG | - |
| Furosemide | DRUG | - |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range...